Maintenance: On Thursday, June 28 2018, 18:00-18:15, maintenance work on the ZORA servers is scheduled. ZORA will not be available during this period. Thank you for your patience.
Honecker, F; Rohlfing, T; Harder, S; Braig, M; Gillis, A J; Glaesener, S; Barett, C; Bokemeyer, C; Buck, F; Brümmendorf, T H; Looijenga, L H; Balabanov, S (2014). Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines. Journal of Proteomics, 96:300-313.
Volk, Martin; Harder, S (2007). Evaluating MT with translations or translators: what is the difference? In: MT-Summit, Copenhagen, 2007 - 2007.
von Minckwitz, G; Harder, S; Hövelmann, S; Jäger, E; Al-Batran, S E; Loibl, S G; Atmaca, A; Cimpoiasu, C; Neumann, A M; Abera, A; Knuth, A L; Kaufmann, M; Jäger, D; Maurer, A B; Wels, W S (2005). Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Research, 7(5):R617.